A Novel image processing technique for weighted particle size distribution assessment.

The objective of the study was to create a reliable method that could be used to evaluate the particle size distribution of samples and pre-mixes in real-world situations, particularly those consisting of typical formulation blends. The goal was to use this method to assess the uniformity of the samples and ensure that they met the required quality standards. The researchers aimed to create a method that could be easily incorporated into the manufacturing process, providing a practical and efficient solution.

A Quantitative Study of US FDA Inspection Data for Drug Manufacturing Sites.

The purpose of this study was to determine if any correlations could be identified from the form 483 observations issued by the US FDA during routine GMP inspections of drug substance and drug product manufacturing sites. The data analysed encompassed inspection observations from 2014 through 2018. The intent of the study is to provide unbiased insight to regulatory trends and to understand any underlying factors that may contribute to a sites non-compliance status.

A Semiquantitative Risk Assessment Methodology Fit for Biopharmaceutical Life Cycle Stages.

This paper introduces an innovative risk assessment tool, a semiquantitative risk determination (SQRD) method designed to address risk on the operational and organizational level with a distinct patient safety perspective. Quality Risk Management (ICH Q9) is a systematic process for the assessment, control, communication, and review of risks to the quality of the drug (medicinal) product across the product life cycle. SQRD is a systematic data-driven risk assessment tool.

A Science and Risk-Based Pragmatic Methodology for Blend and Content Uniformity Assessment.

This paper describes a pragmatic approach that can be applied in assessing powder blend and unit dosage uniformity of solid dose products at Process Design, Process Performance Qualification, and Continued/Ongoing Process Verification stages of the Process Validation lifecycle. The statistically based sampling, testing, and assessment plan was developed due to the withdrawal of the FDA draft guidance for industry "Powder Blends and Finished Dosage Units-Stratified In-Process Dosage Unit Sampling and Assessment." This paper compares the proposed Grouped Area Variance Estimate (GAVE) method with an alternate approach outlining the practicality and statistical rationalization using traditional sampling and analytical methods.

Assessment Methodology for Process Validation Lifecycle Stage 3A.

The paper introduces evaluation methodologies and associated statistical approaches for process validation lifecycle Stage 3A. The assessment tools proposed can be applied to newly developed and launched small molecule as well as bio-pharma products, where substantial process and product knowledge has been gathered. The following elements may be included in Stage 3A: number of 3A batch determination; evaluation of critical material attributes, critical process parameters, critical quality attributes; in vivo in vitro correlation; estimation of inherent process variability (IPV) and PaCS index; process capability and quality dashboard (PCQd); and enhanced control strategy.